Skip to Content
Discovering the causes of cancer and the means of prevention

Publications Search - Abstract View

Title: Treatment of Diamond-Blackfan anemia with recombinant human interleukin-3.
Authors: Gillio AP,  Faulkner LB,  Alter BP,  Reilly L,  Klafter R,  Heller G,  Young DC,  Lipton JM,  Moore MA,  O'Reilly RJ
Journal: Blood
Date: 1993 Aug 1
Branches: CGB
PubMed ID: 8338944
PMC ID: not available
Abstract: This report describes the response of eighteen Diamond-Blackfan anemia (DBA) patients to recombinant human interleukin-3 (rhIL-3). rhIL-3 was administered subcutaneously once daily on an escalating dose schedule (0.5 to 10 micrograms/kg/d). The rhIL-3 dose was escalated every 21 days until erythroid response was attained, grade III or IV nonhematologic toxicity was observed, or the maximum rhIL-3 dose was reached. Four patients experienced clinically significant erythroid responses. Two of the responders were steroid-dependent and transfusion-independent, while two were steroid-independent and transfusion-dependent. Baseline clinical or laboratory parameters, in particular in vitro bone marrow erythroid progenitor assays, were not useful in predicting rhIL-3 response. rhIL-3 administered at 5 to 10 micrograms/kg/d was associated with an increase in total white blood cell count, secondary to increases in neutrophils, eosinophils, and lymphocytes. Patients experienced a dose-dependent elevation in absolute eosinophils across the entire dose range. Two of the responding patients remain on maintenance rhIL-3, without diminution of effect at 244 and 370 + days. rhIL-3 was discontinued in the other two responders, because of the development of deep venous thrombi.